H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $75 billion of capital under management, announced the completion of the sale of Celerion Holdings, Inc. (“Celerion”) to funds affiliated with THL Partners for $1.8 billion. Celerion is a leading clinical pharmacology-focused Contract Research Organization globally, a true category-defining business within the pharmaceutical industry. The transaction marks the latest in a series of successful exits from H.I.G.’s Advantage strategy, which has now completed the sales of St. Croix, United Flow Technologies, and Celerion since the fourth quarter of 2025, for a combined total enterprise value of more than $4.5 billion.
Read the full article: H.I.G. Capital Completes Sale of Celerion, Highlighting a Period of Robust Exit Activity //
Source: https://www.prnewswire.com/news-releases/hig-capital-completes-sale-of-celerion-highlighting-a-period-of-robust-exit-activity-302799796.html